https://www.selleckchem.com/pr....oducts/elacridar-gf1
When comparing current treatments for AS, stat3-p Inh showed a comparable suppression effect on osteogenesis to JAK inhibitor or IL-17A blocker in AS-osteoprogenitor cells. Stat3-p Inh suppressed differentiation and mineralization of AS-osteoprogenitor cells and entheseal cells toward osteoblasts. Micro-CT analysis of hind paws revealed less new bone formation in stat3-p Inh-treated mice than vehicle-treated mice (p = 0.005). Hind paw and spinal new bone formation were similar between stat3-p Inh- and anti-IL-17A-treated SKG
Like
Comment
Share
